Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
Status:
Terminated
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well Linifanib works in treating patients with advanced,
refractory colorectal cancer expressing k-Ras mutations. Linifanib may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth.